Treatment and resistance mechanisms in castration-resistant prostate cancer: new implications for clinical decision making?

References

• Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–386.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. Bethesda M. SEER cancer stat facts: prostate cancer.2020 [cited 2020 Apr 9]. Available from: https://seer.cancer.gov/statfacts/html/prost.html
   Google Scholar
• Roehl KA, Han M, Ramos CG, et al. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol. 2004;172(3):910–914.
   PubMed Web of Science ®Google Scholar
• Freedland SJ, Humphreys EB, Mangold LA, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005;294(4):433–439.
   PubMed Web of Science ®Google Scholar
• Huggins C, Stevens RE Jr., Hodges CV. Studies on prostatic cancer: II. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg. 1941;43(2):209–223.
   Google Scholar
• Gravis G, Fizazi K, Joly F, et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14(2):149–158.
   PubMed Web of Science ®Google Scholar
• Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373(8):737–746.
   PubMed Web of Science ®Google Scholar
• Fizazi K, Jenkins C, Tannock IF. Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra. Ann Oncol. 2015;26(8):1660–1667.
   PubMed Web of Science ®Google Scholar
• Gregory CW, He B, Johnson RT, et al. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res. 2001;61(11):4315–4319.
   PubMed Web of Science ®Google Scholar
• Ryan CJ, Smith MR, Fizazi K, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16(2):152–160.
   PubMed Web of Science ®Google Scholar
• Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012;13(10):983–992.
   PubMed Web of Science ®Google Scholar
• De Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364(21):1995–2005.
   PubMed Web of Science ®Google Scholar
• Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187–1197.
   PubMed Web of Science ®Google Scholar
• Hussain M, Fizazi K, Saad F, et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2018;378(26):2465–2474.
   PubMed Web of Science ®Google Scholar
• Smith MR, Saad F, Chowdhury S, et al. Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med. 2018;378(15):1408–1418.
   PubMed Web of Science ®Google Scholar
• Fizazi K, Shore N, Tammela TL, et al. Darolutamide in nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2019;380(13):1235–1246.
   PubMed Web of Science ®Google Scholar
• Mccrea E, Sissung TM, Price DK, et al. Androgen receptor variation affects prostate cancer progression and drug resistance. Pharmacol Res. 2016;114:152–162.
   PubMed Web of Science ®Google Scholar
• Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol. 1996;14(6):1756–1764.
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Halabi S, Conaway M, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol. 1999;17(8):2506–2513.
   PubMed Web of Science ®Google Scholar
• Berthold DR, Pond GR, Soban F, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol. 2008;26(2):242–245.
   PubMed Web of Science ®Google Scholar
• De Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376(9747):1147–1154.
   PubMed Web of Science ®Google Scholar
• Hansen AR, Massard C, Ott PA, et al. Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study. Ann Oncol. 2018;29(8):1807–1813.
   PubMed Web of Science ®Google Scholar
• Antonarakis ES, Piulats JM, Gross-Goupil M, et al. Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study. J Clin Oncol. 2020;38(5):395–405.
   PubMed Web of Science ®Google Scholar
• Mateo J, Carreira S, Sandhu S, et al. DNA-repair defects and olaparib in metastatic prostate cancer. N Engl J Med. 2015;373(18):1697–1708.
   PubMed Web of Science ®Google Scholar
• Agus DB, Cordon-Cardo C, Fox W, et al. Prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence. J Natl Cancer Inst. 1999;91(21):1869–1876.
   PubMed Web of Science ®Google Scholar
• Yun EJ, Zhou J, Lin CJ, et al. Targeting cancer stem cells in castration-resistant prostate cancer. Clin Cancer Res. 2016;22(3):670–679.
   PubMed Web of Science ®Google Scholar
• Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol. 2005;23(32):8253–8261.
   PubMed Web of Science ®Google Scholar
• Akamatsu S, Inoue T, Ogawa O, et al. Clinical and molecular features of treatment-related neuroendocrine prostate cancer. Int J Urol. 2018;25(4):345–351.
   PubMed Web of Science ®Google Scholar
• Visakorpi T, Hyytinen E, Koivisto P, et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet. 1995;9(4):401–406.
   PubMed Web of Science ®Google Scholar
• Bubendorf L, Kononen J, Koivisto P, et al. Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. Cancer Res. 1999;59(4):803–806.
   PubMed Web of Science ®Google Scholar
• Conteduca V, Wetterskog D, Sharabiani MTA, et al. Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study. Ann Oncol. 2017;28(7):1508–1516.
   PubMed Web of Science ®Google Scholar
• Conteduca V, Jayaram A, Romero-Laorden N, et al. Plasma androgen receptor and docetaxel for metastatic castration-resistant prostate cancer. Eur Urol. 2019;75(3):368–373.
   PubMed Web of Science ®Google Scholar
• Yeh S, Miyamoto H, Shima H, et al. From estrogen to androgen receptor: a new pathway for sex hormones in prostate. Proc Natl Acad Sci USA. 1998;95(10):5527–5532.
   PubMed Web of Science ®Google Scholar
• Culig Z, Hobisch A, Cronauer MV, et al. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res. 1994;54(20):5474–5478.
   PubMed Web of Science ®Google Scholar
• Ferraldeschi R, Nava Rodrigues D, Riisnaes R, et al. PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate. Eur Urol. 2015;67(4):795–802.
   PubMed Web of Science ®Google Scholar
• Rescigno P, Lorente D, Dolling D, et al. Docetaxel Treatment in PTEN- and ERG-aberrant metastatic prostate cancers. Eur Urol Oncol. 2018;1(1):71–77.
   PubMed Web of Science ®Google Scholar
• De Bono JS, De Giorgi U, Rodrigues DN, et al. Randomized phase II study evaluating Akt blockade with Ipatasertib, in combination with abiraterone, in patients with metastatic prostate cancer with and without PTEN loss. Clin Cancer Res. 2019;25(3):928–936.
   PubMed Web of Science ®Google Scholar
• Grasso CS, Wu YM, Robinson DR, et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature. 2012;487(7406):239–243.
   PubMed Web of Science ®Google Scholar
• Robinson D, Van Allen EM, Wu YM, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015;161(5):1215–1228.
   PubMed Web of Science ®Google Scholar
• Taylor BS, Schultz N, Hieronymus H, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010;18(1):11–22.
   PubMed Web of Science ®Google Scholar
• Balk SP. Androgen receptor as a target in androgen-independent prostate cancer. Urology. 2002;60(3Suppl 1):132–138; discussion 138–139.
   Google Scholar
• Carreira S, Romanel A, Goodall J, et al. Tumor clone dynamics in lethal prostate cancer. Sci Transl Med. 2014;6(254):254ra125.
   PubMed Web of Science ®Google Scholar
• Balbas MD, Evans MJ, Hosfield DJ, et al. Overcoming mutation-based resistance to antiandrogens with rational drug design. Elife. 2013;2:e00499.
   PubMed Web of Science ®Google Scholar
• Joseph JD, Lu N, Qian J, et al. A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509. Cancer Discov. 2013;3(9):1020–1029.
   PubMed Web of Science ®Google Scholar
• Korpal M, Korn JM, Gao X, et al. An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide). Cancer Discov. 2013;3(9):1030–1043.
   PubMed Web of Science ®Google Scholar
• Fizazi K, Albiges L, Loriot Y, et al. ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer. Expert Rev Anticancer Ther. 2015;15(9):1007–1017.
   PubMed Web of Science ®Google Scholar
• Jernberg E, Bergh A, Wikström P. Clinical relevance of androgen receptor alterations in prostate cancer. Endocr Connect. 2017;6(8):R146–r161.
   PubMed Web of Science ®Google Scholar
• Annala M, Vandekerkhove G, Khalaf D, et al. Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer. Cancer Discov. 2018;8(4):444–457.
   PubMed Web of Science ®Google Scholar
• Romanel A, Gasi Tandefelt D, Conteduca V, et al. Plasma AR and abiraterone-resistant prostate cancer. Sci Transl Med. 2015;7(312):312re310.
   Web of Science ®Google Scholar
• Hu J, Chen Q. The role of glucocorticoid receptor in prostate cancer progression: from bench to bedside. Int Urol Nephrol. 2017;49(3):369–380.
   PubMed Web of Science ®Google Scholar
• Lorente D, Mateo J, Zafeiriou Z, et al. Switching and withdrawing hormonal agents for castration-resistant prostate cancer. Nat Rev Urol. 2015;12(1):37–47.
   PubMed Web of Science ®Google Scholar
• Sartor AO, Tangen CM, Hussain MH, et al. Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426). Cancer. 2008;112(11):2393–2400.
   PubMed Web of Science ®Google Scholar
• Scher HI, Kelly WK. Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol. 1993;11(8):1566–1572.
   PubMed Web of Science ®Google Scholar
• Kelly WK, Scher HI. Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. J Urol. 1993;149(3):607–609.
   PubMed Web of Science ®Google Scholar
• Akakura K, Akimoto S, Furuya Y, et al. Incidence and characteristics of antiandrogen withdrawal syndrome in prostate cancer after treatment with chlormadinone acetate. Eur Urol. 1998;33(6):567–571.
   PubMed Web of Science ®Google Scholar
• Huan SD, Gerridzen RG, Yau JC, et al. Antiandrogen withdrawal syndrome with nilutamide. Urology. 1997;49(4):632–634.
   PubMed Web of Science ®Google Scholar
• Suzuki H, Okihara K, Miyake H, et al. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade. J Urol. 2008;180(3):921–927.
   PubMed Web of Science ®Google Scholar
• Kojima S, Suzuki H, Akakura K, et al. Alternative antiandrogens to treat prostate cancer relapse after initial hormone therapy. J Urol. 2004;171(2Pt 1):679–683.
   PubMedGoogle Scholar
• Okihara K, Ukimura O, Kanemitsu N, et al. Clinical efficacy of alternative antiandrogen therapy in Japanese men with relapsed prostate cancer after first-line hormonal therapy. Int J Urol. 2007;14(2):128–132.
   PubMed Web of Science ®Google Scholar
• Okegawa T, Nutahara K, Higashihara E. Alternative antiandrogen therapy in patients with castration-resistant prostate cancer: a single-center experience. Int J Urol. 2010;17(11):950–955.
   PubMed Web of Science ®Google Scholar
• Takada T, Ishizuya Y, Okada T, et al. Alternative antiandrogen therapy with flutamide in patients with castration-resistant prostate cancer: a single center experience. Hinyokika Kiyo. 2011;57(6):291–295.
   PubMedGoogle Scholar
• Choi JI, Kim YB, Yang SO, et al. Efficacy of alternative antiandrogen therapy for prostate cancer that relapsed after initial maximum androgen blockade. Korean J Urol. 2011;52(7):461–465.
   PubMedGoogle Scholar
• Lorente D, Omlin A, Ferraldeschi R, et al. Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone. Br J Cancer. 2014;111(12):2248–2253.
   PubMed Web of Science ®Google Scholar
• Dehm SM, Tindall DJ. Alternatively spliced androgen receptor variants. Endocr Relat Cancer. 2011;18(5):R183–196.
   PubMed Web of Science ®Google Scholar
• Liu C, Lou W, Zhu Y, et al. Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer. Clin Cancer Res. 2014;20(12):3198–3210.
   PubMed Web of Science ®Google Scholar
• Jones D, Noble M, Wedge SR, et al. Aurora A regulates expression of AR-V7 in models of castrate resistant prostate cancer. Sci Rep. 2017;7:40957.
   PubMed Web of Science ®Google Scholar
• Ferraldeschi R, Welti J, Powers MV, et al. Second-generation HSP90 inhibitor onalespib blocks mRNA splicing of androgen receptor variant 7 in prostate cancer cells. Cancer Res. 2016;76(9):2731–2742.
   PubMed Web of Science ®Google Scholar
• Suzman DL, Antonarakis ES. Does degree of androgen suppression matter in hormone-sensitive prostate cancer? J Clin Oncol. 2015;33(10):1098–1100.
   PubMed Web of Science ®Google Scholar
• Nishiyama T, Hashimoto Y, Takahashi K. The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer. Clin Cancer Res. 2004;10(21):7121–7126.
   PubMed Web of Science ®Google Scholar
• Chang KH, Ercole CE, Sharifi N. Androgen metabolism in prostate cancer: from molecular mechanisms to clinical consequences. Br J Cancer. 2014;111(7):1249–1254.
   PubMed Web of Science ®Google Scholar
• Hearn JWD, Sweeney CJ, Almassi N, et al. HSD3B1 genotype and clinical outcomes in metastatic castration-sensitive prostate cancer. JAMA Oncol. 2020;6(4):e196496.
   PubMed Web of Science ®Google Scholar
• Norris JD, Ellison SJ, Baker JG, et al. Androgen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancer. J Clin Invest. 2017;127(6):2326–2338.
   PubMed Web of Science ®Google Scholar
• Sun Y, Wang BE, Leong KG, et al. Androgen deprivation causes epithelial-mesenchymal transition in the prostate: implications for androgen-deprivation therapy. Cancer Res. 2012;72(2):527–536.
   PubMed Web of Science ®Google Scholar
• Thiery JP, Acloque H, Huang RY, et al. Epithelial-mesenchymal transitions in development and disease. Cell. 2009;139(5):871–890.
   PubMed Web of Science ®Google Scholar
• Soundararajan R, Paranjape AN, Maity S, et al. EMT, stemness and tumor plasticity in aggressive variant neuroendocrine prostate cancers. Biochim Biophys Acta Rev Cancer. 2018;1870(2):229–238.
   PubMed Web of Science ®Google Scholar
• Montanari M, Rossetti S, Cavaliere C, et al. Epithelial-mesenchymal transition in prostate cancer: an overview. Oncotarget. 2017;8(21):35376–35389.
   PubMedGoogle Scholar
• Soundararajan R, Allegakoen P, Hollander PD, et al. Abstract 4674: targeting cancer stem-cells in aggressive variant prostate cancers. Cancer Res. 2019;79(13 Supplement):4674.
   Web of Science ®Google Scholar
• Corn PG, Heath EI, Zurita A, et al. Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1–2 trial. Lancet Oncol. 2019;20(10):1432–1443.
   PubMed Web of Science ®Google Scholar
• Mckenzie S, Kyprianou N. Apoptosis evasion: the role of survival pathways in prostate cancer progression and therapeutic resistance. J Cell Biochem. 2006;97(1):18–32.
   PubMed Web of Science ®Google Scholar
• Raffo AJ, Perlman H, Chen MW, et al. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res. 1995;55(19):4438–4445.
   PubMed Web of Science ®Google Scholar
• Sonpavde G, Matveev V, Burke JM, et al. Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer. Ann Oncol. 2012;23(7):1803–1808.
   PubMed Web of Science ®Google Scholar
• Stein MN, Hussain M, Stadler WM, et al. A phase II study of AT-101 to overcome Bcl-2–mediated resistance to androgen deprivation therapy in patients with newly diagnosed castration-sensitive metastatic prostate cancer. Clin Genitourin Cancer. 2016;14(1):22–27.
   PubMed Web of Science ®Google Scholar
• Oudard S, Fizazi K, Sengelov L, et al. Cabazitaxel versus docetaxel as first-line therapy for patients with metastatic castration-resistant prostate cancer: a randomized phase III trial-FIRSTANA. J Clin Oncol. 2017;35(28):3189–3197.
   PubMed Web of Science ®Google Scholar
• James ND, Sydes MR, Clarke NW, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387(10024):1163–1177.
   PubMed Web of Science ®Google Scholar
• De Wit R, De Bono J, Sternberg CN, et al. Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer. N Engl J Med. 2019;381(26):2506–2518.
   PubMed Web of Science ®Google Scholar
• Pienta KJ. Preclinical mechanisms of action of docetaxel and docetaxel combinations in prostate cancer. Semin Oncol. 2001;28(4Suppl 15):3–7.
   PubMedGoogle Scholar
• Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer. 2004;4(4):253–265.
   PubMed Web of Science ®Google Scholar
• Thadani-Mulero M, Nanus DM, Giannakakou P. Androgen receptor on the move: boarding the microtubule expressway to the nucleus. Cancer Res. 2012;72(18):4611–4615.
   PubMed Web of Science ®Google Scholar
• Darshan MS, Loftus MS, Thadani-Mulero M, et al. Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. Cancer Res. 2011;71(18):6019–6029.
   PubMed Web of Science ®Google Scholar
• Zhu ML, Horbinski CM, Garzotto M, et al. Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. Cancer Res. 2010;70(20):7992–8002.
   PubMed Web of Science ®Google Scholar
• O’neill AJ, Prencipe M, Dowling C, et al. Characterisation and manipulation of docetaxel resistant prostate cancer cell lines. Mol Cancer. 2011;10:126.
   PubMed Web of Science ®Google Scholar
• Lu Q, Luduena RF. Removal of beta III isotype enhances taxol induced microtubule assembly. Cell Struct Funct. 1993;18(3):173–182.
   PubMed Web of Science ®Google Scholar
• Sekino Y, Han X, Kawaguchi T, et al. TUBB3 reverses resistance to docetaxel and cabazitaxel in prostate cancer. Int J Mol Sci. 2019;20(16):3936.
   Web of Science ®Google Scholar
• Puhr M, Hoefer J, Schafer G, et al. Epithelial-to-mesenchymal transition leads to docetaxel resistance in prostate cancer and is mediated by reduced expression of miR-200c and miR-205. Am J Pathol. 2012;181(6):2188–2201.
   PubMed Web of Science ®Google Scholar
• Duran GE, Wang YC, Francisco EB, et al. Mechanisms of resistance to cabazitaxel. Mol Cancer Ther. 2015;14(1):193–201.
   PubMed Web of Science ®Google Scholar
• Shiota M, Dejima T, Yamamoto Y, et al. Collateral resistance to taxanes in enzalutamide-resistant prostate cancer through aberrant androgen receptor and its variants. Cancer Sci. 2018;109(10):3224–3234.
   PubMed Web of Science ®Google Scholar
• Administration. UFaD. Docetaxel PRESCRIBING INFORMATION. 2013 [cited 2020 May 7]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020449s071lbl.pdf
   Google Scholar
• Administration. UFaD. Cabazitaxel PRESCRIBING INFORMATION. 2010 [cited 2020 May 9]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/201023lbl.pdf
   Google Scholar
• Duran GE, Derdau V, Weitz D, et al. Cabazitaxel is more active than first-generation taxanes in ABCB1(+) cell lines due to its reduced affinity for P-glycoprotein. Cancer Chemother Pharmacol. 2018;81(6):1095–1103.
   PubMed Web of Science ®Google Scholar
• Lombard AP, Liu C, Armstrong CM, et al. ABCB1 mediates cabazitaxel-docetaxel cross-resistance in advanced prostate cancer. Mol Cancer Ther. 2017;16(10):2257–2266.
   PubMed Web of Science ®Google Scholar
• Van Soest RJ, De Morree ES, Kweldam CF, et al. Targeting the androgen receptor confers in vivo cross-resistance between enzalutamide and docetaxel, but not cabazitaxel, in castration-resistant prostate cancer. Eur Urol. 2015;67(6):981–985.
   PubMed Web of Science ®Google Scholar
• Ylitalo EB, Thysell E, Thellenberg-Karlsson C, et al. Marked response to cabazitaxel in prostate cancer xenografts expressing androgen receptor variant 7 and reversion of acquired resistance by anti-androgens. Prostate. 2020;80(2):214–224.
   PubMed Web of Science ®Google Scholar
• Marín-Aguilera M, Codony-Servat J, Reig Ò, et al. Epithelial-to-mesenchymal transition mediates docetaxel resistance and high risk of relapse in prostate cancer. Mol Cancer Ther. 2014;13(5):1270–1284.
   PubMed Web of Science ®Google Scholar
• Galletti G, Matov A, Beltran H, et al. ERG induces taxane resistance in castration-resistant prostate cancer. Nat Commun. 2014;5:5548.
   PubMed Web of Science ®Google Scholar
• Reig Ò, Marín-Aguilera M, Carrera G, et al. TMPRSS2-ERG in blood and docetaxel resistance in metastatic castration-resistant prostate cancer. Eur Urol. 2016;70(5):709–713.
   PubMed Web of Science ®Google Scholar
• Hamid A, Wang XV, Chen Y-H, et al. Luminal B subtype as a predictive biomarker of docetaxel benefit for newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC): a correlative study of E3805 CHAARTED. J clin oncol. 2020;38(6_suppl):162.
   Web of Science ®Google Scholar
• Buttigliero C, Tucci M, Bertaglia V, et al. Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer. Cancer Treat Rev. 2015;41(10):884–892.
   PubMed Web of Science ®Google Scholar
• Tucci M, Zichi C, Buttigliero C, et al. Enzalutamide-resistant castration-resistant prostate cancer: challenges and solutions. Onco Targets Ther. 2018;11:7353–7368.
   PubMed Web of Science ®Google Scholar
• Moilanen AM, Riikonen R, Oksala R, et al. Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies. Sci Rep. 2015;5:12007.
   PubMed Web of Science ®Google Scholar
• Liu Q, Tong D, Liu G, et al. Metformin reverses prostate cancer resistance to enzalutamide by targeting TGF-beta1/STAT3 axis-regulated EMT. Cell Death Dis. 2017;8(8):e3007.
   PubMedGoogle Scholar
• Hamilton RJ, Li J, Naini V, et al. Effect of concomitant medication use on outcomes of treatment and placebo arms of the COU-AA-301 and COU-AA-302 studies of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC). J clin oncol. 2014;32(15_suppl):e16045.
   Web of Science ®Google Scholar
• Mark M, Klingbiel D, Mey U, et al. Impact of addition of metformin to abiraterone in metastatic castration-resistant prostate cancer patients with disease progressing while receiving abiraterone treatment (MetAb-Pro): phase 2 pilot study. Clin Genitourin Cancer. 2019;17(2):e323–e328.
   PubMed Web of Science ®Google Scholar
• De Bono JS, Chowdhury S, Feyerabend S, et al. Antitumour activity and safety of enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with abiraterone acetate plus prednisone for >/=24 weeks in Europe. Eur Urol. 2018;74(1):37–45.
   PubMed Web of Science ®Google Scholar
• Mostaghel EA, Marck BT, Plymate SR, et al. Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res. 2011;17(18):5913–5925.
   PubMed Web of Science ®Google Scholar
• Nadiminty N, Tummala R, Liu C, et al. NF-kappaB2/p52 induces resistance to enzalutamide in prostate cancer: role of androgen receptor and its variants. Mol Cancer Ther. 2013;12(8):1629–1637.
   PubMed Web of Science ®Google Scholar
• Antonarakis ES, Lu C, Luber B, et al. Clinical significance of androgen receptor splice variant-7 mRNA detection in circulating tumor cells of men with metastatic castration-resistant prostate cancer treated with first- and second-line abiraterone and enzalutamide. J Clin Oncol. 2017;35(19):2149–2156.
   PubMed Web of Science ®Google Scholar
• Antonarakis ES, Lu C, Luber B, et al. Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer. JAMA Oncol. 2015;1(5):582–591.
   PubMed Web of Science ®Google Scholar
• Armstrong AJ, Halabi S, Luo J, et al. Prospective multicenter validation of androgen receptor splice variant 7 and hormone therapy resistance in high-risk castration-resistant prostate cancer: the PROPHECY study. J Clin Oncol. 2019;37(13):1120–1129.
   PubMed Web of Science ®Google Scholar
• Scher HI, Lu D, Schreiber NA, et al. Association of AR-V7 on circulating tumor cells as a treatment-specific biomarker with outcomes and survival in castration-resistant prostate cancer. JAMA Oncol. 2016;2(11):1441–1449.
   PubMed Web of Science ®Google Scholar
• Brown LC, Lu C, Antonarakis ES, et al. Androgen receptor variant-driven prostate cancer II: advances in clinical investigation. Prostate Cancer Prostatic Dis. 2020;23:367–380.
   Web of Science ®Google Scholar
• Cancer Genome Atlas Research N. The molecular taxonomy of primary prostate cancer. Cell. 2015;163(4):1011–1025.
   PubMed Web of Science ®Google Scholar
• Aggarwal R, Huang J, Alumkal JJ, et al. Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study. J Clin Oncol. 2018;36(24):2492–2503.
   PubMed Web of Science ®Google Scholar
• Abida W, Cyrta J, Heller G, et al. Genomic correlates of clinical outcome in advanced prostate cancer. Proc Natl Acad Sci USA. 2019;116(23):11428–11436.
   PubMed Web of Science ®Google Scholar
• Chen WS, Aggarwal R, Zhang L, et al. Genomic drivers of poor prognosis and enzalutamide resistance in metastatic castration-resistant prostate cancer. Eur Urol. 2019;76(5):562–571.
   PubMed Web of Science ®Google Scholar
• Wyatt AW, Azad AA, Volik SV, et al. Genomic alterations in cell-free DNA and enzalutamide resistance in castration-resistant prostate cancer. JAMA Oncol. 2016;2(12):1598–1606.
   PubMed Web of Science ®Google Scholar
• Del Re M, Fogli S, Derosa L, et al. The role of drug-drug interactions in prostate cancer treatment: focus on abiraterone acetate/prednisone and enzalutamide. Cancer Treat Rev. 2017;55:71–82.
   PubMed Web of Science ®Google Scholar
• Preer SC, Hoffmann MF, Preer R, et al. Polymorphic cytochrome P450 enzymes (CYPs) and their role in personalized therapy. PLoS One. 2013;8(12):e82562.
   PubMed Web of Science ®Google Scholar
• Pinto N, Dolan ME. Clinically relevant genetic variations in drug metabolizing enzymes. Curr Drug Metab. 2011;12(5):487–497.
   PubMed Web of Science ®Google Scholar
• Mega JL, Simon T, Collet JP, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. Jama. 2010;304(16):1821–1830.
   PubMed Web of Science ®Google Scholar
• Holmes DR Jr., Dehmer GJ, Kaul S, et al. ACCF/AHA clopidogrel clinical alert: approaches to the FDA “boxed warning”: a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents and the American Heart Association endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. J Am Coll Cardiol. 2010;56(4):321–341.
   PubMed Web of Science ®Google Scholar
• Van Der Wouden CH, Cambon-Thomsen A, Cecchin E, et al. Implementing pharmacogenomics in Europe: design and implementation strategy of the ubiquitous pharmacogenomics consortium. Clin Pharmacol Ther. 2017;101(3):341–358.
   PubMed Web of Science ®Google Scholar
• Ang JW, Tan MH, Tay MH, et al. Outcomes of dose-attenuated docetaxel in Asian patients with castrate-resistant prostate cancer. Ann Acad Med Singap. 2017;46(5):195–201.
   PubMed Web of Science ®Google Scholar
• Kita Y, Shimizu Y, Inoue T, et al. Reduced-dose docetaxel for castration-resistant prostate cancer has no inferior impact on overall survival in Japanese patients. Int J Clin Oncol. 2013;18(4):718–723.
   PubMed Web of Science ®Google Scholar
• Zhou T, Zeng S-X, Ye D-W, et al. A multicenter, randomized clinical trial comparing the three-weekly docetaxel regimen plus prednisone versus mitoxantone plus prednisone for Chinese patients with metastatic castration refractory prostate cancer. PloS One. 2015;10(1):e0117002.
   PubMed Web of Science ®Google Scholar
• Poon DMC, Chan T, Chan K, et al. Preliminary efficacy and tolerability of chemohormonal therapy in metastatic hormone-naïve prostate cancer: the first real-life experience in Asia. Asia Pac J Clin Oncol. 2018;14(4):347–352.
   PubMed Web of Science ®Google Scholar
• Poon DMC, Ng J, Chan K. Importance of cycles of chemotherapy and postdocetaxel novel therapies in metastatic castration-resistant prostate cancer. Prostate Int. 2015;3(2):51–55.
   PubMed Web of Science ®Google Scholar
• Halabi S, Dutta S, Tangen CM, et al. Clinical outcomes in men of diverse ethnic backgrounds with metastatic castration-resistant prostate cancer. Ann Oncol. 2020;31(7):930–941.
   PubMedGoogle Scholar
• Thompson I, Tangen C, Tolcher A, et al. Association of African-American ethnic background with survival in men with metastatic prostate cancer. J Natl Cancer Inst. 2001;93(3):219–225.
   PubMed Web of Science ®Google Scholar
• Tangen CM, Hussain MH, Higano CS, et al. Improved overall survival trends of men with newly diagnosed M1 prostate cancer: a SWOG phase III trial experience (S8494, S8894 and S9346). J Urol. 2012;188(4):1164–1169.
   PubMed Web of Science ®Google Scholar
• Halabi S, Small EJ, Vogelzang NJ, et al. Impact of race on survival in men with metastatic hormone-refractory prostate cancer. Urology. 2004;64(2):212–217.
   PubMed Web of Science ®Google Scholar
• Halabi S, Vogelzang NJ, Ou SS, et al. Clinical outcomes by age in men with hormone refractory prostate cancer: a pooled analysis of 8 Cancer and Leukemia Group B (CALGB) studies. J Urol. 2006;176(1):81–86.
   PubMed Web of Science ®Google Scholar
• Halabi S, Dutta S, Tangen CM, et al. Overall survival of black and white men with metastatic castration-resistant prostate cancer treated with docetaxel. J Clin Oncol. 2019;37(5):403–410.
   PubMed Web of Science ®Google Scholar
• Mcnamara MA, George DJ, Ramaswamy K, et al. Overall survival by race in chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate or enzalutamide. J clin oncol. 2019;37(7_suppl):212.
   Web of Science ®Google Scholar
• George DJ, Heath EI, Sartor AO, et al. Abi Race: a prospective, multicenter study of black (B) and white (W) patients (pts) with metastatic castrate resistant prostate cancer (mCRPC) treated with abiraterone acetate and prednisone (AAP). J clin oncol. 2018;36(18_suppl):LBA5009.
   Web of Science ®Google Scholar
• Administration. UFaD. Abiraterone acetate PRESCRIBING INFORMATION. 2011 [cited 2020 May 12]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202379lbl.pdf
   Google Scholar
• Agency. EM. Summary of product characteristics: ERLEADA. 2019 [cited 2020 May 7]. Available from: https://www.ema.europa.eu/en/documents/product-information/erleada-epar-product-information_en.pdf
   Google Scholar
• Llc. JO. Erleada (apalutamide) US prescribing infor- mation. 2018 [cited 2020 May 7]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210951s000lbl.pdf
   Google Scholar
• Agency. EM. Jevtana: EPAR - product information. 2019 [cited 2020 May 9]. Available from: https://www.ema.europa.eu/en/documents/product-information/jevtana-epar-product-information_en.pdf
   Google Scholar
• Agency. EM. Taxotere EPAR product information. 2020. [cited 2020 May 9]. Available from: https://www.ema.europa.eu/en/documents/product-information/taxotere-epar-product-information_en.pdf
   Google Scholar
• Inc. APU. Xtandi (enzalutamide) US prescribing information. 2018 [cited 2019 May 7]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/203415s014lbl.pdf
   Google Scholar
• Agency. EM. Summary of product characteristics: XTANDI. 2019 [cited 2020 May 7]. Available from: https://www.ema.europa.eu/en/documents/product-information/xtandi-epar-product-information_en.pdf
   Google Scholar
• Hansten PD, Horn JR. The top 100 drug interactions: a guide to patient management. USA: H & H Publications; 2004.
   Google Scholar
• Administration. UFaD. Drug development and drug interactions: table of substrates, inhibitors and inducers. [cited 2020 May 7]. Available from: https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers
   Google Scholar
• De Gregori S, De Gregori M, Ranzani GN, et al. Morphine metabolism, transport and brain disposition. Metab Brain Dis. 2012;27(1):1–5.
   PubMed Web of Science ®Google Scholar
• Ge S, Tu Y, Hu M. Challenges and opportunities with predicting in vivo phase II metabolism via glucuronidation from in vitro data. Current Pharmacol Rep. 2016;2(6):326–338.
   PubMedGoogle Scholar
• Agency EM. European Public Assessment Report (EPAR): zytiga (abiraterone acetate). London: European Medicines Agency; 2016.
   Google Scholar
• Acharya M, Gonzalez M, Mannens G, et al. A phase I, open-label, single-dose, mass balance study of 14C-labeled abiraterone acetate in healthy male subjects. Xenobiotica. 2013;43(4):379–389.
   PubMed Web of Science ®Google Scholar
• Gibbons JA, De Vries M, Krauwinkel W, et al. Pharmacokinetic drug interaction studies with enzalutamide. Clin Pharmacokinet. 2015;54(10):1057–1069.
   PubMed Web of Science ®Google Scholar
• Apalutamide for prostate cancer. Aust Prescr. 2019 Feb;42(1):32–33.DOI: 10.18773/austprescr.2018.072. Epub 2018 Dec 13. PMID: 30765908; PMCID: PMC6370612.
   PubMedGoogle Scholar
• Zurth C, Koskinen M, Fricke R, et al. Drug-drug interaction potential of darolutamide: in vitro and clinical studies. Eur J Drug Metab Pharmacokinet. 2019;44(6):747–759.
   PubMed Web of Science ®Google Scholar
• Bayer HealthCare Pharmaceuticals Inc. Nubeqa (darolutamide) US prescribing information. 2019 [cited 2020 Apr 26]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212099Orig1s000lbl.pdf
   Google Scholar
• Shore N, Zurth C, Fricke R, et al. Evaluation of clinically relevant drug-drug interactions and population pharmacokinetics of darolutamide in patients with nonmetastatic castration-resistant prostate cancer: results of pre-specified and post hoc analyses of the phase III ARAMIS trial. Target Oncol. 2019;14(5):527–539.
   PubMed Web of Science ®Google Scholar
• Small EJ, Saad F, Chowdhury S, et al. Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer. Ann Oncol. 2019;30(11):1813–1820.
   PubMed Web of Science ®Google Scholar
• Borgmann H, Lallous N, Ozistanbullu D, et al. Moving towards precision urologic oncology: targeting enzalutamide-resistant prostate cancer and mutated forms of the androgen receptor using the novel inhibitor darolutamide (ODM-201). Eur Urol. 2018;73(1):4–8.
   PubMed Web of Science ®Google Scholar
• Feng FY, Thomas S, Gormley M, et al. Identifying molecular determinants of response to apalutamide (APA) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) in the SPARTAN trial. J clin oncol. 2019;37(7_suppl):42.
   Web of Science ®Google Scholar
• Saad F, Graff JN, Hadaschik BA, et al. Molecular determinants of prostate specific antigen (PSA) kinetics and clinical response to apalutamide (APA) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) in SPARTAN. J clin oncol. 2020;38(15_suppl):5521.
   Web of Science ®Google Scholar
• Liede A, Arellano J, Hechmati G, et al. International prevalence of nonmetastatic (M0) castration-resistant prostate cancer (CRPC). J Clin Oncol. 2013;31(15_suppl):e16052.
   Web of Science ®Google Scholar
• Castro E, Goh C, Olmos D, et al. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol. 2013;31(14):1748–1757.
   PubMed Web of Science ®Google Scholar
• Mateo J, Porta N, Bianchini D, et al. Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2020;21(1):162–174.
   PubMed Web of Science ®Google Scholar
• Hussain M, Mateo J, Fizazi K, et al. PROfound: phase III study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations. Ann Oncol. 2019;30:v881–v882.
   PubMedGoogle Scholar
• Abida W, Campbell D, Patnaik A, et al. Preliminary results from the TRITON2 study of rucaparib in patients (pts) with DNA damage repair (DDR)-deficient metastatic castration-resistant prostate cancer (mCRPC): updated analyses. Ann Oncol. 2019;30:v327–v328.
   Google Scholar
• Abida W, Campbell D, Patnaik A, et al. Non-BRCA DNA damage repair gene alterations and response to the PARP inhibitor rucaparib in metastatic castration-resistant prostate cancer: analysis from the phase 2 TRITON2 study. Clin Cancer Res. 2020. DOI:10.1158/1078-0432.Ccr-20-0394.
   Web of Science ®Google Scholar
• Li H, Liu Z-Y, Wu N, et al. PARP inhibitor resistance: the underlying mechanisms and clinical implications. Mol Cancer. 2020;19(1):107.
   PubMed Web of Science ®Google Scholar
• Antonarakis ES, Madison R, Snider J, et al. Association of BRCA alteration (alt) type with real-world (RW) outcomes to PARP inhibitors (PARPi) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC). J clin oncol. 2020;38(15_suppl):5527.
   Web of Science ®Google Scholar
• Lombard AP, Liu C, Armstrong CM, et al. Overexpressed ABCB1 induces olaparib-taxane cross-resistance in advanced prostate cancer. Transl Oncol. 2019;12(7):871–878.
   PubMed Web of Science ®Google Scholar
• Cheng HH, Pritchard CC, Boyd T, et al. Biallelic inactivation of BRCA2 in platinum-sensitive metastatic castration-resistant prostate cancer. Eur Urol. 2016;69(6):992–995.
   PubMed Web of Science ®Google Scholar
• Pomerantz MM, Spisak S, Jia L, et al. The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer. Cancer. 2017;123(18):3532–3539.
   PubMed Web of Science ®Google Scholar
• Gongora ABL, Canedo F, De Melo ALA, et al. Tumor lysis syndrome after platinum-based chemotherapy in castration-resistant prostate cancer with a BRCA2 mutation: a case report. Clin Genitourin Cancer. 2019;17(1):e61–e64.
   PubMed Web of Science ®Google Scholar
• Mateo J, Cheng HH, Beltran H, et al. Clinical outcome of prostate cancer patients with germline DNA repair mutations: retrospective analysis from an international study. Eur Urol. 2018;73(5):687–693.
   PubMed Web of Science ®Google Scholar
• Abida W, Cheng ML, Armenia J, et al. Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade. JAMA Oncol. 2019;5(4):471–478.
   PubMed Web of Science ®Google Scholar
• Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409–413.
   PubMed Web of Science ®Google Scholar
• Middha S, Zhang L, Nafa K, et al. Reliable pan-cancer microsatellite instability assessment by using targeted next-generation sequencing data. JCO Precis Oncol. 2017;2017:PO.17.00084. doi: 10.1200/PO.17.00084. Epub 2017 Oct 3. PMID: 30211344; PMCID: PMC6130812.
   PubMedGoogle Scholar
• Martin AM, Nirschl TR, Nirschl CJ, et al. Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance. Prostate Cancer Prostatic Dis. 2015;18(4):325–332.
   PubMed Web of Science ®Google Scholar
• Bishop JL, Sio A, Angeles A, et al. PD-L1 is highly expressed in Enzalutamide resistant prostate cancer. Oncotarget. 2015;6(1):234–242.
   PubMedGoogle Scholar
• Jones W, Griffiths K, Barata PC, et al. PSMA theranostics: review of the current status of PSMA-targeted imaging and radioligand therapy. Cancers (Basel). 2020;12(6):1367.
   Web of Science ®Google Scholar
• Hofman MS, Emmett L, Sandhu SK, et al. TheraP: A randomised phase II trial of 177Lu-PSMA-617 (LuPSMA) theranostic versus cabazitaxel in metastatic castration resistant prostate cancer (mCRPC) progressing after docetaxel: initial results (ANZUP protocol 1603). J clin oncol. 2020;38(15_suppl):5500.
   Web of Science ®Google Scholar
• Khalaf DJ, Annala M, Taavitsainen S, et al. Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial. Lancet Oncol. 2019;20(12):1730–1739.
   PubMed Web of Science ®Google Scholar
• Morris MJ, Heller G, Bryce A et al. Alliance A031201: A phase III trial of enzalutamide vs enzalutamide, abiraterone, and prednisone for metastatic castration resistant prostate cancer (mCRPC). 2019.
   Google Scholar
• Efstathiou E, Titus M, Wen S, et al. Enzalutamide in combination with abiraterone acetate in bone metastatic castration-resistant prostate cancer patients. Eur Urol Oncol. 2020;3(1):119–127.
   PubMed Web of Science ®Google Scholar
• Clarke N, Wiechno P, Alekseev B, et al. Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2018;19(7):975–986.
   PubMed Web of Science ®Google Scholar